United in its passion for helping women with cancer and specializing in the development of potentially first-in-class medicines, Context Therapeutics has embarked on a mission to develop treatments for patients with hormone-driven cancers.
In August 2022, Context announced a clinical trial collaboration and supply agreement with the Menarini Group to evaluate ONA-XR in combination with Menarini’s oral selective estrogen receptor degrader, elacestrant.
In this video, Context Therapeutics’ CEO and Co-founder, Martin Lehr, and Menarini Group CEO, Elcin Barker Ergun, discuss the collaboration.
For more information, visit Edison’s profile page for Context Therapeutics and see the latest update.
Metals & Mining
Get access to the very latest content matched to your personal investment style.